Efficacy and Safety of Clascoterone Cream 1% in Facial Acne Vulgaris

NCT06403501 | Recruiting Phase 3

• 1 other identifier: LWY23090C
• Study Type: interventional
• Target: 692
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of this study is to determine the safety and efficacy of clascoterone cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.

Conditions

Acne Vulgaris

Keywords

Acne Vulgaris

Outcome Measures

Primary Outcomes (3)

• Percentage of Participants Achieving Success in Investigator's Global Assessment (IGA)

  Percentage of subjects in each treatment group achieving "success" at Week 12, with "success" defined as an IGA score of "clear (score=0)" or "almost clear (score=1)" and at least a two-point reduction in IGA compared to Baseline.

  Week 12

• Change From Baseline in Non-inflammatory Lesion (NIL) Counts

  Absolute change from Baseline in non-inflammatory lesion counts in each treatment group at Week 12.

  Week 12

• Change From Baseline in Inflammatory Lesion (IL) Counts

  Absolute change from Baseline in inflammatory lesion counts in each treatment group at Week 12.

  Week 12

Secondary Outcomes (4)

• Change From Baseline in Total Lesion Counts

  Week 12

• Percent Change From Baseline in Total Lesion Counts

  Week 12

• Percent Change From Baseline in Inflammatory Lesion Counts

  Week 12

• Percent Change From Baseline in Non-inflammatory Lesion Counts

  Week 12

Study Arms (2)

Clascoterone Cream 1%

EXPERIMENTAL

Clascoterone Cream 1% (Winlevi)

Drug: Clascoterone

Vehicle cream

PLACEBO COMPARATOR

Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.

Drug: Vehicle cream

Interventions

Clascoterone DRUG

Clascoterone Cream 1% (Winlevi) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.

Also known as: Winlevi (brand name)

Clascoterone Cream 1%

Vehicle cream DRUG

Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.

Vehicle cream

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosed with facial acne vulgaris (which includes the nose) from moderate to severe, has an Investigator's Global Assessment (IGA) score of 3 or 4; with at least 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones);
• Male or female, 12 years of age or older;
• Subjects aged 18 years or older are required to provide informed consent and sign the written informed consent. A subject under 18 years of age must provide written informed assent and be accompanied by the parent or legal guardian at the time of consent signing.

You may not qualify if:

• Subject has greater than two (2) facial nodules;
• Subject has any skin pathology or condition that could interfere with the investigator's clinical evaluation of the investigational drug;
• Subject has used topical and systemic anti-acne medications or therapies;
• Subject has received hormonal therapy for acne treatment;
• Subject has used a skincare product with acne removal effect;
• Subject has other serious underlying diseases such as mental illness or malignant tumors;
• Subject has any of the clinically significant laboratory test indicators at screening;
• Subject has known hypersensitivity or previous allergic reaction to multiple drugs, or any of the active or inactive components of the test articles;
• Subject engaged in drug abuse or excessive alcohol intake;
• Subject has uncontrolled hypertension; Subject has poorly controlled diabetes;
• Subject is pregnant, lactating, or is planning to become pregnant during the study (both male and female); subject has positive pregnancy test result; subject is unable to practice highly effective contraception methods during the trial and within 3 months after the end of the trial;
• Subject is currently enrolled or was enrolled in other clinical trials within 3 months prior to the initiation of treatment;
• Subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this clinical trial.

Sponsors & Collaborators

• Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.: lead

Study Sites (1)

Huashan Hospital, Fudan University

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Clascoterone

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 30, 2024
• First Posted: May 8, 2024
• Study Start: May 20, 2024
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: July 9, 2025

Record last verified: 2025-07

Locations

CN (1)